<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neuromuscul Disord</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neuromuscul. Disord</journal-id>
      <journal-title-group>
        <journal-title>Neuromuscular Disorders</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0960-8966</issn>
      <issn pub-type="epub">1873-2364</issn>
      <publisher>
        <publisher-name>Pergamon Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24183479</article-id>
      <article-id pub-id-type="pmc">4018985</article-id>
      <article-id pub-id-type="publisher-id">S0960-8966(13)00933-4</article-id>
      <article-id pub-id-type="doi">10.1016/j.nmd.2013.08.002</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gallenm&#xFC;ller</surname>
            <given-names>Constanze</given-names>
          </name>
          <xref rid="af035" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xFC;ller-Felber</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <xref rid="af040" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dusl</surname>
            <given-names>Marina</given-names>
          </name>
          <xref rid="af035" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stucka</surname>
            <given-names>Rolf</given-names>
          </name>
          <xref rid="af035" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guergueltcheva</surname>
            <given-names>Velina</given-names>
          </name>
          <xref rid="af035" ref-type="aff">a</xref>
          <xref rid="af045" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blaschek</surname>
            <given-names>Astrid</given-names>
          </name>
          <xref rid="af040" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>von der Hagen</surname>
            <given-names>Maja</given-names>
          </name>
          <xref rid="af050" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huebner</surname>
            <given-names>Angela</given-names>
          </name>
          <xref rid="af050" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>Juliane S.</given-names>
          </name>
          <xref rid="af055" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lochm&#xFC;ller</surname>
            <given-names>Hanns</given-names>
          </name>
          <xref rid="af055" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abicht</surname>
            <given-names>Angela</given-names>
          </name>
          <email>Angela.Abicht@med.uni-muenchen.de</email>
          <xref rid="af035" ref-type="aff">a</xref>
          <xref rid="af060" ref-type="aff">f</xref>
          <xref rid="cor1" ref-type="corresp">&#x204E;</xref>
        </contrib>
      </contrib-group>
      <aff id="af035"><label>a</label>Friedrich-Baur-Institut, Ludwig Maximilians University, Munich, Germany</aff>
      <aff id="af040"><label>b</label>Haunersche Kinderklinik, Ludwig Maximilians University, Munich, Germany</aff>
      <aff id="af045"><label>c</label>Clinic of Neurology, University Hospital Alexandrovska, Sofia, Bulgaria</aff>
      <aff id="af050"><label>d</label>Children&#x2019;s Hospital, Technical University Dresden, Germany</aff>
      <aff id="af055"><label>e</label>Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom</aff>
      <aff id="af060"><label>f</label>Medical Genetics Center, Munich, Germany</aff>
      <author-notes>
        <corresp id="cor1"><label>&#x204E;</label>Corresponding author at: Ludwig Maximilians University, Friedrich-Baur-Institut, Ziemssenstr. 1a, D-80336 Munich, Germany. Tel.: +49 89 2180 78180; fax: +49 89 2180 78184. <email>Angela.Abicht@med.uni-muenchen.de</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>24</volume>
      <issue>1</issue>
      <fpage>31</fpage>
      <lpage>35</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>2</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2013 The Authors</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous disorders characterized by a neuromuscular transmission defect. In recent years, causative mutations have been identified in atleast 15 genes encoding proteins of the neuromuscular junction. Mutations in <italic>MUSK</italic> are known as a very rare genetic cause of CMS and have been described in only three families, world-wide. Consequently, the knowledge about efficient drug therapy is very limited. We identified a novel missense mutation (p.Asp38Glu) heteroallelic to a genomic deletion affecting exons 2&#x2013;3 of <italic>MUSK</italic> as cause of a limb-girdle CMS in two brothers of Turkish origin. Clinical symptoms included fatigable limb weakness from early childhood on. Upon diagnosis of a <italic>MUSK</italic>-related CMS at the age of 16 and 13&#xA0;years, respectively, treatment with salbutamol was initiated leading to an impressive improvement of clinical symptoms, while treatment with esterase inhibitors did not show any benefit. Our findings highlight the importance of a molecular diagnosis in CMS and demonstrate considerable similarities between patients with MUSK and DOK7-related CMS in terms of clinical phenotype and treatment options.</p>
      </abstract>
      <kwd-group>
        <title>Abbreviations</title>
        <kwd>AChR, acetylcholine receptor</kwd>
        <kwd>AChE, acetylcholine esterase</kwd>
        <kwd>CK, creatine kinase</kwd>
        <kwd>CMAP, compound muscle action potential</kwd>
        <kwd>CMS, congenital myasthenic syndrome</kwd>
      </kwd-group>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Congenital myasthenic syndromes</kwd>
        <kwd>Neuromuscular transmission</kwd>
        <kwd>MUSK-related CMS</kwd>
        <kwd>Salbutamol treatment</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0005">
      <label>1</label>
      <title>Introduction</title>
      <p>Congenital myasthenic syndromes (CMS) comprise a group of hereditary disorders characterized by a neuromuscular transmission defect. In recent years, disease-associated mutations have been identified in several genes that encode different presynaptic, synaptic, and postsynaptic proteins of the neuromuscular junction <xref rid="b0005 b0010 b0015" ref-type="bibr">[1&#x2013;3]</xref>. Postsynaptic CMS caused by mutations identified in <italic>RAPSN</italic>, <italic>DOK7</italic>, <italic>AGRN</italic>, and <italic>MUSK</italic> further underlined the key role of the agrin&#x2013;MuSK&#x2013;rapsyn pathway for the organization and maintenance of the postsynaptic scaffold <xref rid="b0020 b0025 b0030" ref-type="bibr">[4&#x2013;6]</xref>. MuSK, the muscle-specific receptor tyrosine kinase, plays a central signaling role in this pathway and is essential for prepatterning acetylcholine receptors (AChRs) in muscle prior to innervation and for agrin-induced AChR clustering: Agrin, a heparin sulfate proteoglycan supplied by motor neurons, binds to LRP4 (low density lipoprotein receptor related protein 4) expressed in muscle <xref rid="b0035 b0040 b0045" ref-type="bibr">[7&#x2013;9]</xref>, leading to activation of MuSK <xref rid="b0050" ref-type="bibr">[10]</xref>. In the developing nerve terminal, activation of MuSK is a critical step and results in the recruitment of several downstream kinases, clustering of essential postsynaptic proteins including Rapsyn and the AChRs, synapse-specific gene transcription and the generation of retrograde signals that regulate presynaptic differentiation <xref rid="b0055 b0060 b0065" ref-type="bibr">[11&#x2013;13]</xref>.</p>
      <p>The MuSK protein includes a large ectodomain containing IgG-like motif, a transmembrane helix and a cytoplasmic tyrosine kinase domain. Its activation is characterized by an induced autophosphorylation and an increased kinase activity. MuSK requires a dual activation, extracellularly by agrin and intracellularly by Dok7. Agrin does not interact directly with MuSK but binds LRP4. LRP4 and MuSK interact via their respective extracellular domains <xref rid="b0045 b0070" ref-type="bibr">[9,14]</xref>. The crystal structure of MuSK and Dok7 revealed that the phosphotyrosine-binding domain (PTB domain) of Dok7 forms an integrated, dimeric structural unit that dimerizes MuSK and thereby facilitates trans-autophosphorylation of tyrosines in the MuSK activation loop <xref rid="b0075" ref-type="bibr">[15]</xref>.</p>
      <p>The gene <italic>MUSK</italic> is located on chromosome 9q31.3-q32 and comprises 14 exons. Autosomal recessive <italic>MUSK</italic> mutations have been first identified in a single CMS patient <xref rid="b0080" ref-type="bibr">[16]</xref> harbouring two heteroallelic mutations, a frameshift mutation (c.220insC) and a missense mutation (p.V790M). We recently reported on CMS caused by a homozygous missense mutation (p.P344R) in <italic>MUSK</italic> in five affected sibs from a consanguineous Sudanese family. The affected proline is located in the Frizzled-like cysteine-rich domain, a part of the extracellular domain of MuSK <xref rid="b0085" ref-type="bibr">[17]</xref>. In addition, two missense mutations (p.M605I and p.A727V), both located in the kinase domain of MuSK have been identified, recently <xref rid="b0090" ref-type="bibr">[18]</xref>.</p>
    </sec>
    <sec sec-type="materials|methods" id="s0010">
      <label>2</label>
      <title>Materials and methods</title>
      <sec id="s0015">
        <label>2.1</label>
        <title>Patients, DNA samples, linkage analysis, sequencing</title>
        <p>We analyzed two affected brothers and their unaffected parents by linkage analysis and direct sequencing as previously described <xref rid="b0095" ref-type="bibr">[19]</xref>. After reducing the number of candidate genes using a linkage approach with DNA marker sets of the known CMS and congenital myopathy genes <xref rid="b0100" ref-type="bibr">[20]</xref> several known genes to cause CMS when mutated (<italic>COLQ</italic>, <italic>DOK7, RAPSN, CHAT, CHRNE, CHRNA1, CHRND, CHRNE, GFPT1, and MUSK</italic>) were analyzed in the younger brother as in the index patient. Paternity was confirmed by a set of highly polymorphic microsatellite markers using the &#x201C;Identifiler-plus&#x201D;-Kit (Applied Biosystems, Carlsbad, California).</p>
      </sec>
      <sec id="s0020">
        <label>2.2</label>
        <title>cDNA analysis</title>
        <p>A muscle biopsy specimen was obtained from the elder brother. RNA was isolated from muscle tissue using the RNeasy Mini Kit (QIAGEN). cDNA was synthesized from RNA using the Transcriptor One-Step RT-PCR Kit with exon-specific primers of the <italic>MUSK</italic> gene according to the manufacturer&#x2019;s recommendations (exon 1: 5&#x2032;-CCTTCAGCGGAACTGAGAAA-3&#x2032; and exon 4: 5&#x2032;-TGGTTTGGGATTACCCATTG-3&#x2032;). Corresponding PCR products were analyzed by agarose gel electrophoresis, excised from the gel, and analyzed by direct sequencing.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s0025">
      <label>3</label>
      <title>Results</title>
      <sec id="s0030">
        <label>3.1</label>
        <title>Case report</title>
        <p>We report on two affected brothers from a Turkish non consanguineous family. After having achieved motor milestones at time and walking independently at the age of 12&#xA0;months, his mother noted that her first child (patient 1) used furniture to pull himself up to a stand. Over the next few years a reduced exercise tolerance became more obvious. When the older brother presented to the neuropediatric department at the age of 3.5&#xA0;years, an abnormal exercise tolerance was also noted in the younger brother (patient 2) who was nine months old at this time. Subsequent follow-up revealed a progressive worsening of muscle endurance in both patients leading to an inability to walk in the afternoon in patient 1 at the age of 15&#xA0;years. The younger brother is ambulatory and able to climb stairs at school but is easily exhausted. Both brothers manifest a proximal limb and facial muscle weakness without any bulbar and ocular symptoms such as ptosis or limitation of eye movements (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). A muscle biopsy at age 9&#xA0;years in the elder brother revealed minimal myopathic changes. Sonographic examination of the muscle showed an increased echo signal of the quadriceps femoris muscle in patient 1 and a normal pattern in his brother.</p>
        <p>At the age of 11&#xA0;years, repetitive stimulation of the accessorius nerve in patient 1 resulted in a 19% decrement of the CMAP. Repetitive CMAPs were not observed after a single nerve stimulus. CK levels were normal, and serum antibodies against AChR negative. A trial with oral pyridostigmine bromide in patient 1 at the age of 10&#xA0;years resulted in a worsening of the symptoms and was stopped after 3&#xA0;weeks of treatment. A second trial with pyridostigmine showed a similar effect. Salbutamol was tried at the age of 16 and 13&#xA0;years, respectively, in both patients. At that time patient 1 was unable to get out of the wheelchair without support in the afternoon. Patient 2 had to use a bannister to climb stairs in the afternoon. One week after starting salbutamol (2&#xA0;&#xD7;&#xA0;4&#xA0;mg/day) patient 1 was able to climb stairs again using a bannister. Patient 2 was able to climb stairs without any aids. There was a further improvement of symptoms after increasing the daily dosage of salbutamol to 3&#xA0;&#xD7;&#xA0;4&#xA0;mg in both brothers.</p>
      </sec>
      <sec id="s0035">
        <label>3.2</label>
        <title>Mutation analysis</title>
        <p>Sequence analysis of the coding region of <italic>MUSK</italic> revealed a seemingly homozygous T to A transition in exon 2 at nucleotide position 114 leading to an amino acid exchange (p.Asp38Glu) in both affected brothers. The sequence variant was not identified in the relevant SNP databases including 5000 exomes, and not in 50 ethnically matched control chromosomes. Segregation analysis in the family revealed that the mutation was present heterozygously in the mother but was not present in the father. We hypothesized that a heteroallelic deletion may have been missed by our analysis of genomic DNA. PCR amplification of cDNA derived from muscle tissue RNA of the older brother by a set of primers spanning exon 1 to exon 4 of <italic>MUSK</italic> revealed the presence of an additional band of 100&#xA0;bp which was shorter than the expected 400&#xA0;bp wild-type product. In the sequencing reaction of the 100&#xA0;bp-band exons 2&#x2013;3 were missing and exon 1 was spliced to exon 4 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s0040">
      <label>4</label>
      <title>Discussion</title>
      <p>Mutations in <italic>MUSK</italic> are known as a very rare genetic cause of CMS and have been described in only three families, so far. We identified a novel missense mutation c.114T&#xA0;&gt;&#xA0;A; p.Asp38Glu heteroallelic to a genomic deletion encompassing exons 2&#x2013;3 of <italic>MUSK</italic> detected by polymerase chain reaction (PCR)-based methods that explain a limb-girdle CMS in two affected brothers of a Turkish family.</p>
      <p>The patients&#x2019; fatigable and varying weakness presenting as a limb-girdle phenotype and the decremental response of the CMAP on repetitive stimulation were consistent with a myasthenic phenotype. However, the absence of ocular symptoms, the ineffectiveness of pyridostigmine treatment, and the absence of genetic findings made the distinction to a congenital myopathy challenging.</p>
      <p>The clinical phenotype in our patients largely resembles patients with DOK7 mutations including the pronounced weakness of limb girdle musculature, normal eye movements, and ineffectiveness of esterase inhibitors. The clinical characteristics together with the mutations in the <italic>MUSK</italic> gene suggested a therapeutic trial with salbutamol that led to a dramatic clinical improvement of the patient&#x15B; symptoms within a week after years of moderate disease progression. The clinical phenotype we have seen in our patients has been described in the few previously described <italic>MUSK</italic> patients. We may hypothesize that MuSK deficiency, similar to Dok7 deficiency, results in a defect of synapse formation or maintenance (&#x201C;synaptopathy&#x201D;) which does not respond to esterase inhibitor treatment. While mutations in <italic>MUSK</italic> are found less frequently than <italic>DOK7</italic> mutations, we would suggest testing of the <italic>DOK7</italic> gene first, and then the <italic>MUSK</italic> gene, in patients with limb-girdle CMS unresponsive to esterase inhibitors. In contrast, most patients with LG-CMS and tubular aggregates responding to esterase inhibitors carry mutations in <italic>GFPT1</italic> or <italic>DPAGT</italic>.</p>
      <p>In CMS patients due to <italic>COLQ</italic>, <italic>DOK7</italic> and <italic>LAMB2</italic> mutations sympathomimetics like ephedrine and salbutamol have been shown to have a clear beneficial effect without major side effects <xref rid="b0105 b0110" ref-type="bibr">[21,22]</xref>. In contrast, only moderate improvement with albuterol sulfate and no improvement with ephedrine has previously been reported for a single patient with CMS caused by two missense mutations in <italic>MUSK</italic>
<xref rid="b0090" ref-type="bibr">[18]</xref>. A dramatic clinical effect of salbutamol treatment is a novel finding for patients with <italic>MUSK</italic>-related CMS. However, the mode of action of sympathomimetic agents in some forms of CMS is unknown.</p>
      <p>The mutation c.114T&#xA0;&gt;&#xA0;A; p.Asp38Glu identified in our patients is not described as a pathogenic mutation or as a polymorphism. Pathogenicity is supported by the segregation of the mutation with the disease phenotype in the family and by its absence from 50 ethnically matched control chromosomes and relevant databases including 5000 exomes. A bioinformatic analysis using PolyPhen-2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/ggi/pph2" id="ir0005">http://genetics.bwh.harvard.edu/ggi/pph2</ext-link>) <xref rid="b0115" ref-type="bibr">[23]</xref> predicts the exchange of the highly conserved amino acid Asp to be probably damaging with a score of 0.988 (sensitivity: 0.72; specificity: 0.96). Three of the four previously reported missense mutations are located in the C-terminal domain of the protein corresponding to the conserved catalytic tyrosine kinase domain: V790M <xref rid="b0080" ref-type="bibr">[16]</xref>, M605I and A727V <xref rid="b0090" ref-type="bibr">[18]</xref>. Further functional studies for those mutations indicated the inability of MuSK mutants to interact with Dok-7 as a major determinant of the molecular pathogenesis <xref rid="b0080 b0090 b0120" ref-type="bibr">[16,18,24]</xref>. In contrast to three of the four previously reported missense mutations, our missense mutation p.Asp38Glu reported is located in the extracellular protein domain, even closer to the N-terminus than the missense mutation p.P344R previously reported by us <xref rid="b0085" ref-type="bibr">[17]</xref>. Functional studies have not been carried out for either of the N-terminus mutations. It can be speculated that mutations of the extracellular part of the protein do not affect the interaction with Dok-7 which takes part intracellularly <xref rid="b0075" ref-type="bibr">[15]</xref> but the extracellular activation effected by agrin. The affected aspartate at position 38 is part of a beta-strand of Ig-like domain 1 (Ig1) of the MuSK extracellular region that is known to form a homodimer mediated by a hydrophobic face <xref rid="b0125" ref-type="bibr">[25]</xref>. Thus, the missense mutation p.Asp38Glu might interfere with the dimerization of MuSK and the subsequent association with LRP4 to form a functional LRP4-MuSK complex <xref rid="b0040 b0045" ref-type="bibr">[8,9]</xref>. Recent studies suggest a role of Wnt in synapse formation. Interestingly, there is also indication that the extracellular domain of MuSK is involved in Wnt binding <xref rid="b0130 b0135" ref-type="bibr">[26,27]</xref>. Alternatively, the mutation might cause misfolding of Ig1, leading to retention of MuSK inside the cell. However, as functional studies have not been carried out this remains speculative. The second mutation identified in our patients is a two-exons deletion. In general, genomic deletions are relatively common, but often not detected by standard diagnostic sequencing. Our finding of a genomic deletion of MUSK further emphasizes the importance of dosage sensitive screening techniques in molecular genetic testing.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="b0005">
        <label>1</label>
        <element-citation publication-type="journal" id="h0005">
          <person-group person-group-type="author">
            <name>
              <surname>Engel</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>X.M.</given-names>
            </name>
            <name>
              <surname>Selcen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sine</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>What have we learned from the congenital myasthenic syndromes</article-title>
          <source>J Mol Neurosci</source>
          <volume>40</volume>
          <year>2010</year>
          <fpage>143</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">19688192</pub-id>
        </element-citation>
      </ref>
      <ref id="b0010">
        <label>2</label>
        <element-citation publication-type="journal" id="h0130">
          <person-group person-group-type="author">
            <name>
              <surname>Engel</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Congenital Myasthenic Syndromes in 2012</article-title>
          <source>Curr Neurol Neurosci Rep</source>
          <volume>12</volume>
          <year>2012</year>
          <fpage>92</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="pmid">21997714</pub-id>
        </element-citation>
      </ref>
      <ref id="b0015">
        <label>3</label>
        <element-citation publication-type="journal" id="h0010">
          <person-group person-group-type="author">
            <name>
              <surname>Engel</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Current status of the congenital myasthenic syndromes</article-title>
          <source>Neuromuscul Disord</source>
          <volume>22</volume>
          <year>2012</year>
          <fpage>99</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="pmid">22104196</pub-id>
        </element-citation>
      </ref>
      <ref id="b0020">
        <label>4</label>
        <element-citation publication-type="journal" id="h0015">
          <person-group person-group-type="author">
            <name>
              <surname>Gautam</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Noakes</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Moscoso</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Defective neuromuscular synaptogenesis in agrin-deficient mutant mice</article-title>
          <source>Cell</source>
          <volume>85</volume>
          <year>1996</year>
          <fpage>525</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="pmid">8653788</pub-id>
        </element-citation>
      </ref>
      <ref id="b0025">
        <label>5</label>
        <element-citation publication-type="journal" id="h0020">
          <person-group person-group-type="author">
            <name>
              <surname>Gautam</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Noakes</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Mudd</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice</article-title>
          <source>Nature</source>
          <volume>377</volume>
          <year>1995</year>
          <fpage>232</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="pmid">7675108</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>6</label>
        <element-citation publication-type="journal" id="h0025">
          <person-group person-group-type="author">
            <name>
              <surname>DeChiara</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Bowen</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Valenzuela</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo</article-title>
          <source>Cell</source>
          <volume>85</volume>
          <year>1996</year>
          <fpage>501</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="pmid">8653786</pub-id>
        </element-citation>
      </ref>
      <ref id="b0035">
        <label>7</label>
        <element-citation publication-type="journal" id="h0030">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stiegler</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Cameron</surname>
              <given-names>T.O.</given-names>
            </name>
          </person-group>
          <article-title>Lrp4 is a receptor for Agrin and forms a complex with MuSK</article-title>
          <source>Cell</source>
          <volume>135</volume>
          <year>2008</year>
          <fpage>334</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">18848351</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>8</label>
        <element-citation publication-type="journal" id="h0035">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>LRP4 serves as a coreceptor of agrin</article-title>
          <source>Neuron</source>
          <volume>60</volume>
          <year>2008</year>
          <fpage>285</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">18957220</pub-id>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>9</label>
        <element-citation publication-type="journal" id="h0040">
          <person-group person-group-type="author">
            <name>
              <surname>Zong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Structural basis of agrin-LRP4-MuSK signaling</article-title>
          <source>Genes Dev</source>
          <volume>26</volume>
          <year>2012</year>
          <fpage>247</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="pmid">22302937</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>10</label>
        <element-citation publication-type="journal" id="h0045">
          <person-group person-group-type="author">
            <name>
              <surname>Glass</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Yancopoulos</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation</article-title>
          <source>Curr Opin Neurobiol</source>
          <volume>7</volume>
          <year>1997</year>
          <fpage>379</fpage>
          <lpage>384</lpage>
          <pub-id pub-id-type="pmid">9232805</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>11</label>
        <element-citation publication-type="journal" id="h0050">
          <person-group person-group-type="author">
            <name>
              <surname>Finn</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pendergast</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction</article-title>
          <source>Nat Neurosci</source>
          <volume>6</volume>
          <year>2003</year>
          <fpage>717</fpage>
          <lpage>723</lpage>
          <pub-id pub-id-type="pmid">12796783</pub-id>
        </element-citation>
      </ref>
      <ref id="b0060">
        <label>12</label>
        <element-citation publication-type="journal" id="h0055">
          <person-group person-group-type="author">
            <name>
              <surname>Strochlic</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cartaud</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cartaud</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions</article-title>
          <source>Bioessays</source>
          <volume>27</volume>
          <year>2005</year>
          <fpage>1129</fpage>
          <lpage>1135</lpage>
          <pub-id pub-id-type="pmid">16237673</pub-id>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>13</label>
        <element-citation publication-type="journal" id="h0060">
          <person-group person-group-type="author">
            <name>
              <surname>Ghazanfari</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Muscle specific kinase: organiser of synaptic membrane domains</article-title>
          <source>Int J Biochem Cell Biol</source>
          <volume>43</volume>
          <year>2011</year>
          <fpage>295</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="pmid">20974278</pub-id>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>14</label>
        <element-citation publication-type="journal" id="h0065">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Coldefy</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Burden</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK)</article-title>
          <source>J Biol Chem</source>
          <volume>286</volume>
          <year>2011</year>
          <fpage>40624</fpage>
          <lpage>40630</lpage>
          <pub-id pub-id-type="pmid">21969364</pub-id>
        </element-citation>
      </ref>
      <ref id="b0075">
        <label>15</label>
        <element-citation publication-type="journal" id="h0070">
          <person-group person-group-type="author">
            <name>
              <surname>Bergamin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hallock</surname>
              <given-names>P.T.</given-names>
            </name>
            <name>
              <surname>Burden</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization</article-title>
          <source>Mol Cell</source>
          <volume>39</volume>
          <year>2010</year>
          <fpage>100</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">20603078</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>16</label>
        <element-citation publication-type="journal" id="h0075">
          <person-group person-group-type="author">
            <name>
              <surname>Chevessier</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Faraut</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ravel-Chapuis</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>MUSK, a new target for mutations causing congenital myasthenic syndrome</article-title>
          <source>Hum Mol Genet</source>
          <volume>13</volume>
          <year>2004</year>
          <fpage>3229</fpage>
          <lpage>3240</lpage>
          <pub-id pub-id-type="pmid">15496425</pub-id>
        </element-citation>
      </ref>
      <ref id="b0085">
        <label>17</label>
        <element-citation publication-type="journal" id="h0080">
          <person-group person-group-type="author">
            <name>
              <surname>Mihaylova</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Salih</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Mukhtar</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes</article-title>
          <source>Neurology</source>
          <volume>73</volume>
          <year>2009</year>
          <fpage>1926</fpage>
          <lpage>1928</lpage>
          <pub-id pub-id-type="pmid">19949040</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>18</label>
        <element-citation publication-type="journal" id="h0085">
          <person-group person-group-type="author">
            <name>
              <surname>Maselli</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Arredondo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cagney</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction</article-title>
          <source>Hum Mol Genet</source>
          <volume>19</volume>
          <year>2010</year>
          <fpage>2370</fpage>
          <lpage>2379</lpage>
          <pub-id pub-id-type="pmid">20371544</pub-id>
        </element-citation>
      </ref>
      <ref id="b0095">
        <label>19</label>
        <element-citation publication-type="journal" id="h0090">
          <person-group person-group-type="author">
            <name>
              <surname>Abicht</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dusl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gallenmuller</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: a study of 680 patients</article-title>
          <source>Hum Mutat</source>
          <volume>33</volume>
          <year>2012</year>
          <fpage>1474</fpage>
          <lpage>1484</lpage>
          <pub-id pub-id-type="pmid">22678886</pub-id>
        </element-citation>
      </ref>
      <ref id="b0100">
        <label>20</label>
        <element-citation publication-type="journal" id="h0095">
          <person-group person-group-type="author">
            <name>
              <surname>von der Hagen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schallner</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kaindl</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Facing the genetic heterogeneity in neuromuscular disorders: linkage analysis as an economic diagnostic approach towards the molecular diagnosis</article-title>
          <source>Neuromuscul Disord</source>
          <volume>16</volume>
          <year>2006</year>
          <fpage>4</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">16378727</pub-id>
        </element-citation>
      </ref>
      <ref id="b0105">
        <label>21</label>
        <element-citation publication-type="journal" id="h0135">
          <person-group person-group-type="author">
            <name>
              <surname>Burke</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hiscock</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations</article-title>
          <source>Neuromuscul Disord</source>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="b0110">
        <label>22</label>
        <element-citation publication-type="journal" id="h0100">
          <person-group person-group-type="author">
            <name>
              <surname>Liewluck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Selcen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Engel</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia</article-title>
          <source>Muscle Nerve</source>
          <volume>44</volume>
          <year>2011</year>
          <fpage>789</fpage>
          <lpage>794</lpage>
          <pub-id pub-id-type="pmid">21952943</pub-id>
        </element-citation>
      </ref>
      <ref id="b0115">
        <label>23</label>
        <element-citation publication-type="journal" id="h0105">
          <person-group person-group-type="author">
            <name>
              <surname>Adzhubei</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Peshkin</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>A method and server for predicting damaging missense mutations</article-title>
          <source>Nat Meth</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>248</fpage>
          <lpage>249</lpage>
        </element-citation>
      </ref>
      <ref id="b0120">
        <label>24</label>
        <element-citation publication-type="journal" id="h0110">
          <person-group person-group-type="author">
            <name>
              <surname>Okada</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The muscle protein Dok-7 is essential for neuromuscular synaptogenesis</article-title>
          <source>Science</source>
          <volume>312</volume>
          <year>2006</year>
          <fpage>1802</fpage>
          <lpage>1805</lpage>
          <pub-id pub-id-type="pmid">16794080</pub-id>
        </element-citation>
      </ref>
      <ref id="b0125">
        <label>25</label>
        <element-citation publication-type="journal" id="h0115">
          <person-group person-group-type="author">
            <name>
              <surname>Stiegler</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Burden</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK</article-title>
          <source>J Mol Biol</source>
          <volume>364</volume>
          <year>2006</year>
          <fpage>424</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="pmid">17011580</pub-id>
        </element-citation>
      </ref>
      <ref id="b0130">
        <label>26</label>
        <element-citation publication-type="journal" id="h0120">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>L.R.</given-names>
            </name>
            <name>
              <surname>Gribble</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Syrett</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Granato</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Initiation of synapse formation by Wnt-induced MuSK endocytosis</article-title>
          <source>Development</source>
          <volume>139</volume>
          <year>2012</year>
          <fpage>1023</fpage>
          <lpage>1033</lpage>
          <pub-id pub-id-type="pmid">22318632</pub-id>
        </element-citation>
      </ref>
      <ref id="b0135">
        <label>27</label>
        <element-citation publication-type="journal" id="h0125">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Wnt proteins regulate acetylcholine receptor clustering in muscle cells</article-title>
          <source>Mol Brain</source>
          <volume>5</volume>
          <year>2012</year>
          <fpage>7</fpage>
          <pub-id pub-id-type="pmid">22309736</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack id="ak005">
      <title>Acknowledgements</title>
      <p>We wish to thank the patients and their family for participating in this study. AA, MD, AH, MH, RS and HL are members of the German Muscular Dystrophy Network (MD-NET (<ext-link ext-link-type="uri" xlink:href="http://www.md-net.org" id="ir0010">www.md-net.org</ext-link>). The Institute of Genetic Medicine in Newcastle is part of the MRC centre for Neuromuscular Diseases. Newcastle University and MD-NET are partners of the TREAT-NMD Alliance (<ext-link ext-link-type="uri" xlink:href="http://www.treat-nmd.eu" id="ir0015">www.treat-nmd.eu</ext-link>). JSM and HL are supported by a grant from the Medical Research Council UK (reference G1002274, grant ID 98482). VG is a research fellow of the Alexander von Humboldt Foundation. AA is supported by a grant from the Deutsche Forschungsgemeinschaft (Ab 130/2-1).</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig. 1</label>
      <caption>
        <p>The two brothers before salbutamol treatment at age 15 and 12&#xA0;years, respectively. No obvious ptosis is present in both siblings.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Fig. 2</label>
      <caption>
        <p>Detection of the putative deletion allele by PCR amplification of cDNA derived from muscle tissue RNA of the older brother (patient 1). The expected product of 400&#xA0;bp in length was found in the control sample and in the patient. The heteroallelic deletion detected in the patient is represented by an additional PCR product of 100&#xA0;bp. The sequence analysis of the 100&#xA0;bp-band revealed a lack of exons 2&#x2013;3 and exon 1 is spliced to exon 4. Sequence analysis revealed that the mutation c.114T&#xA0;&gt;&#xA0;A was only present in the longer PCR-product of the patient but not in the short product. The presence of putative intronic splice-site mutations was excluded by sequencing 100&#xA0;bp of the 5&#x2032;-prime and 3&#x2032;-prime flanking regions of exons 1&#x2013;4.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
